《大行报告》富瑞下调三生制药(01530.HK)目标价至9元评级“持有”

阿斯达克财经2023-01-18

富瑞发表研究报告指，三生制药(01530.HK) 的核心产品特比澳(TPIAO)获中国工信部审核，用于治疗在儿童或青少年的慢性原发性免疫性血小板减少症(ITP)，数据显示产品三期临床研究已达到预设有效率主要终点，见效快并具良好安全性。该行表示，特比澳用于治疗成人ITP及化疗引起的血小板减少症(CIT)早于2006年上市，产品自2018至2021年的销售额复合年增长率为23%，占三生制药2021年...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2304574955?lang=zh_CN&edition=full","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","is_english":false,"pubTime":"2023-01-18 09:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2304574955","market":"hk","top_or_hot":-1,"title":"《大行报告》富瑞下调三生制药(01530.HK)目标价至9元  评级“持有”","media":"阿斯达克财经","content":"<div>\n<p>富瑞发表研究报告指，三生制药(01530.HK) 的核心产品特比澳(TPIAO)获中国工信部审核，用于治疗在儿童或青少年的慢性原发性免疫性血小板减少症(ITP)，数据显示产品三期临床研究已达到预设有效率主要终点，见效快并具良好安全性。该行表示，特比澳用于治疗成人ITP及化疗引起的血小板减少症(CIT)早于2006年上市，产品自2018至2021年的销售额复合年增长率为23%，占三生制药2021年...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1239807/latest-news/HK6\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《大行报告》富瑞下调三生制药(01530.HK)目标价至9元  评级“持有”</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《大行报告》富瑞下调三生制药(01530.HK)目标价至9元  评级“持有”\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-18 09:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1239807/latest-news/HK6><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>富瑞发表研究报告指，三生制药(01530.HK) 的核心产品特比澳(TPIAO)获中国工信部审核，用于治疗在儿童或青少年的慢性原发性免疫性血小板减少症(ITP)，数据显示产品三期临床研究已达到预设有效率主要终点，见效快并具良好安全性。该行表示，特比澳用于治疗成人ITP及化疗引起的血小板减少症(CIT)早于2006年上市，产品自2018至2021年的销售额复合年增长率为23%，占三生制药2021年...</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1239807/latest-news/HK6\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1239807/latest-news/HK6","article_id":"2304574955","we_media_id":null,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2304574955","pubTimestamp":1674006840,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"富瑞发表研究报告指，三生制药的核心产品特比澳获中国工信部审核，用于治疗在儿童或青少年的慢性原发性免疫性血小板减少症，数据显示产品三期临床研究已达到预设有效率主要终点，见效快并具良好安全性。考虑到公司的产品管线、市场竞争、合作、监管等因素，富瑞将三生制药目标价由10元降至9元，评级“持有”。","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"01530":"三生制药"},"translate_title":"[Big Bank Report] Furui lowered the target price of Sansheng Pharmaceutical (01530. HK) to 9 yuan rating \"held\"","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01530":1,"SSRX":1},"content_text":"富瑞发表研究报告指，三生制药(01530.HK) 的核心产品特比澳(TPIAO)获中国工信部审核，用于治疗在儿童或青少年的慢性原发性免疫性血小板减少症(ITP)，数据显示产品三期临床研究已达到预设有效率主要终点，见效快并具良好安全性。该行表示，特比澳用于治疗成人ITP及化疗引起的血小板减少症(CIT)早于2006年上市，产品自2018至2021年的销售额复合年增长率为23%，占三生制药2021年总收入的48%，预计潜在的适应症扩展将进一步扩大公司收入来源。另外，公司旗下用于治疗脱发的外用药蔓迪(Mandi)于去年上半年在同类产品中市占率达72%，更成为阿里健康(00241.HK) 及京东健康(06618.HK) “双11”活动的非处方药销售排名第一。考虑到公司的产品管线、市场竞争、合作、监管等因素，富瑞将三生制药目标价由10元降至9元，评级“持有”。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2023-01-17 16:25。)","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2304574955"}

《大行报告》富瑞下调三生制药(01530.HK)目标价至9元 评级“持有”

精彩评论

《大行报告》富瑞下调三生制药(01530.HK)目标价至9元评级“持有”